Cost-utility analysis of Amevive™ (alefacept) in the treatment of patients with moderate-to-severe psoriasis

被引：0
|
作者：
Iskedjian, M
Barkovsky, L
Desjardins, O
Walker, JH
Dorkalam, M
Shear, N
Einarson, TR
机构：
[1] PharmIdeas Res & Consulting Inc, Oakville, ON, Canada
[2] Brock Univ, St Catharines, ON L2S 3A1, Canada
[3] Biogen Idec Canada Inc, Mississauga, ON, Canada
[4] Univ Toronto, Toronto, ON, Canada
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)62869-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：331 / 331
页数：1
相关论文
共 50 条
  • [41] Guselkumab in the treatment of moderate-to-severe plaque psoriasis
    Lopez-Sanchez, Cristina
    Puig, Lluis
    [J]. IMMUNOTHERAPY, 2020, 12 (06) : 355 - 371
  • [42] Guselkumab for the treatment of moderate-to-severe plaque psoriasis
    Yang, Eric J.
    Sanchez, Isabelle M.
    Beck, Kristen
    Sekhon, Sahil
    Wu, Jashin J.
    Bhutani, Tina
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (04) : 333 - 344
  • [43] Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States
    Jia, Xiaoying
    Zhao, Yang
    Carrico, Justin
    Brodtkorb, Thor-Henrik
    Mendelsohn, Alan M.
    Lowry, Simon
    Feldman, Steve
    Wu, Jashin J.
    Armstrong, April W.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 740 - 748
  • [44] Treating patients with moderate-to-severe psoriasis vulgaris
    Kessler, Timothy R.
    [J]. JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2022, 35 (03): : 28 - 35
  • [45] COST-UTILITY ANALYSIS OF CERTOLIZUMAB PEGOL VERSUS ALTERNATIVE TUMOR NECROSIS FACTOR-INHIBITORS, FOR THE TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS IN SPAIN
    Villoro, R.
    Hidalgo, A.
    Ferro, B.
    Talavera, P.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A310 - A311
  • [46] Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis
    Reich, Kristian
    Nestle, Frank O.
    Wu, Ying
    Bala, Mohan
    Eisenberg, Debra
    Guzzo, Cynthia
    Li, Shu
    Dooley, Lisa T.
    Griffiths, Christopher E. M.
    [J]. EUROPEAN JOURNAL OF DERMATOLOGY, 2007, 17 (05) : 381 - 386
  • [47] Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis
    Talamonti, M.
    Galluzzo, M.
    Teoli, M.
    Bavetta, M.
    Chimenti, S.
    Costanzo, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (06) : E34 - E34
  • [48] Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate-to-severe psoriasis
    Augustin, Matthias
    Mrowietz, Ulrich
    Willsmann-Theis, Dagmar
    Gerdes, Sascha
    Fotiou, Konstantinos
    Schuster, Christopher
    Mert, Can
    Holzkaemper, Thorsten
    Behrens, Frank
    Pinter, Andreas
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024,
  • [49] DIAGNOSIS AND TREATMENT HISTORY BEFORE PSORIASIS DIAGNOSIS AMONG PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
    Feldman, S. R.
    Zhao, Y.
    Hur, P.
    Liu, J. S.
    Herrera, V
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A156 - A156
  • [50] TREATMENT SATISFACTION AMONG PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN BRAZIL
    Lopes, N.
    Suarez, R. M.
    Sabbag, C. Y.
    Kobata, C. M.
    Takemoto, M. S.
    Pertel, P.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A902 - A902
12345